Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Technology evaluation: EMD-273063, EMD Lexigen.

Ion Niculescu-Duvaz1

  • 1CRC Laboratory, Institute of Cancer Research, 15 Cotswold Road, Sutton, Surrey, SM2 5NG, UK. ion@icr.ac.uk

Current Opinion in Molecular Therapeutics
|November 13, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Potent BRAF kinase inhibitors based on 2,4,5-trisubstituted imidazole with naphthyl and benzothiophene 4-substituents.

Bioorganic & medicinal chemistry·2013
Same author

Primary melanoma of the CNS in children is driven by congenital expression of oncogenic NRAS in melanocytes.

Cancer discovery·2013
Same author

BRAF as a therapeutic target: a patent review (2006 - 2012).

Expert opinion on therapeutic patents·2013
Same author

RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors.

The New England journal of medicine·2012
Same author

Small molecule inhibitors of BRAF in clinical trials.

Bioorganic & medicinal chemistry letters·2012
Same author

Nilotinib and MEK inhibitors induce synthetic lethality through paradoxical activation of RAF in drug-resistant chronic myeloid leukemia.

Cancer cell·2011
Same journal

Gene therapy: Have the risks associated with viral vectors been solved?

Current opinion in molecular therapeutics·2011
Same journal

Teduglutide, a glucagon-like peptide-2 analog for the treatment of gastrointestinal diseases, including short bowel syndrome.

Current opinion in molecular therapeutics·2010
Same journal

Dulaglutide, a long-acting GLP-1 analog fused with an Fc antibody fragment for the potential treatment of type 2 diabetes.

Current opinion in molecular therapeutics·2010
Same journal

Corticorelin, a synthetic human corticotropin-releasing factor analog, for the treatment of peritumoral brain edema.

Current opinion in molecular therapeutics·2010
Same journal

Mogamulizumab, a humanized mAb against C-C chemokine receptor 4 for the potential treatment of T-cell lymphomas and asthma.

Current opinion in molecular therapeutics·2010
Same journal

Gevokizumab, an anti-IL-1β mAb for the potential treatment of type 1 and 2 diabetes, rheumatoid arthritis and cardiovascular disease.

Current opinion in molecular therapeutics·2010
See all related articles

EMD-273063, an antibody/cytokine fusion, combines anti-GD2 antibody 14.18 with IL-2 for potential cancer therapy. It is under investigation for neuroblastoma and melanoma treatment.

Area of Science:

  • Oncology
  • Immunotherapy
  • Biotechnology

Background:

  • Neuroblastoma and melanoma are aggressive cancers with limited treatment options.
  • Targeting the GD2 antigen presents a promising strategy for cancer therapy.
  • Interleukin-2 (IL-2) is a cytokine with immunomodulatory properties.

Purpose of the Study:

  • To evaluate the potential of EMD-273063, an antibody/cytokine fusion protein, as a novel cancer therapeutic.
  • To investigate the preclinical and clinical development of EMD-273063 for neuroblastoma and melanoma.

Main Methods:

  • EMD-273063 is engineered as a fusion protein linking a humanized anti-GD2 antibody (14.18) to two IL-2 molecules.
  • Preclinical studies are assessing efficacy and safety for neuroblastoma.
  • Phase I clinical trials are evaluating safety and tolerability in melanoma patients.

Related Experiment Videos

Main Results:

  • Data from preclinical studies are expected to inform further development for neuroblastoma.
  • Phase I trials will provide initial safety and pharmacokinetic data for melanoma.

Conclusions:

  • EMD-273063 represents a novel approach in cancer immunotherapy by combining targeted antibody delivery with cytokine stimulation.
  • Further clinical investigation is warranted to determine the therapeutic benefit of EMD-273063 in neuroblastoma and melanoma.